number of downloads : ?
File
language
eng
Author
Okimoto, Tamio Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University, Japan
Description
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
Subject
ceritinib
interstitial lung disease
anaplastic lymphoma kinase
adverse event
Journal Title
Internal medicine
Volume
59
Issue
2
Start Page
253
End Page
256
ISSN
0918-2918
ISSN(Online)
1349-7235
Published Date
2019
DOI
Publisher
一般社団法人 日本内科学会
Publisher Transcription
イッパン シャダンホウジン ニホン ナイカ ガッカイ
Publisher Aalternative
The Japanese Society of Internal Medicine
NII Type
Journal Article
Format
PDF
Text Version
著者版
Gyoseki ID
e38014
OAI-PMH Set
Faculty of Medicine